Redcare Pharmacy highlights digital health. Redcare Pharmacy stock falls 1.30 percent
Published on 10/27/2026 at 11:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDigital healthcare and upcoming results
- Redcare Pharmacy highlighted e-prescriptions at an October 23, 2026 healthcare event.
- Full-year 2026 revenue growth guidance stands at 16% to 18% after the September 28, 2026 update.
- Redcare Pharmacy stock trades at EUR 76.00 at 11:00 a.m. CET at Lang & Schwarz on October 27, 2026, 1.30 percent below the Xetra close of October 26, 2026.
- The Q3 2026 interim statement is scheduled for October 29, 2026.
Redcare Pharmacy (NL0012044747) was trading at EUR 76.00 at Lang & Schwarz on October 27, 2026 at 11:00 a.m. CET, down 1.30 percent versus the Xetra close of October 26, 2026 at EUR 77.00. In a release dated October 23, 2026, Redcare Pharmacy highlighted e-prescriptions and digital healthcare after a Berlin event held on October 15. The company said it had around 15 million active customers.
Three events shape the timeline
On September 28, 2026, Redcare Pharmacy raised full-year 2026 total revenue growth guidance to 16% to 18% from 15% to 17%. On October 14, 2026, the company made one chief executive appointment, naming Peter Schmid von Linstow to replace Olaf Heinrich, as Finanztrends reported on October 21. On October 23, 2026, Redcare published its digital healthcare event summary, including the 15 million customer figure.
What does the new strategy mean?
The immediate operating test is still prescription growth. Redcare's September guidance put German prescription revenue at EUR 730 million to EUR 760 million for full-year 2026, compared with EUR 680 million to EUR 720 million previously, while adjusted EBITDA margin guidance stayed at 2.5% to 3.0%. The combination gives the new leadership a clear benchmark before the next report.
Dates investors can measure
Redcare Pharmacy is scheduled to publish its third-quarter 2026 interim statement on October 29, 2026, followed by its 2026 annual report on March 4, 2027. The October release will provide the first full quarterly test of the updated outlook.
Stock is below its yearly high
Redcare Pharmacy has a market capitalization of EUR 1.5 billion as of October 27, 2026. Its 52-week range is EUR 30.20 to EUR 82.55, placing the current euro quote below the upper end of that span.
Redcare Pharmacy was trading at EUR 76.00 at Lang & Schwarz on October 27, 2026 at 11:00 a.m. CET, 1.30 percent below the Xetra close of October 26, 2026 at EUR 77.00. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy stock facts
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 27, 2026, 11:00 a.m. CET): EUR 76.00
- Change versus Xetra close: minus 1.30 percent
- Xetra close (October 26, 2026): EUR 77.00
- Market capitalization: EUR 1.5 billion (as of October 27, 2026)
- 52-week range: EUR 30.20-EUR 82.55 (as of October 27, 2026)
- Sector / Industry: Healthcare / Medical - Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
